The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels

被引:11
作者
Testa, R
Marcovina, SM
机构
[1] Univ Washington, NW Lipid Res Labs, Seattle, WA 98103 USA
[2] Ist Nazl Riposo & Cura Anziani VEII, I-60121 Ancona, Italy
关键词
lipoprotein(a); plasmin formation; fibrinolysis;
D O I
10.1007/s005990050077
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Lipoprotein(a) levels are largely genetically determined and are linked to increased risk. of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the: close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin Followed by addition of tissue plasminogen activator. We then measured the lime course of plasmin formation, determined as hydrolysis of H-D-valyl-L-leucyl-L-lysinc-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r(S)=-0.46, P=0.002), and multiple regression analysis indicated that I-his relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.
引用
收藏
页码:128 / 132
页数:5
相关论文
共 24 条
[1]   EFFECTS OF LIPOPROTEIN(A) ON THE BINDING OF PLASMINOGEN TO FIBRIN AND ITS ACTIVATION BY FIBRIN-BOUND TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
ANGLESCANO, E ;
HERVIO, L ;
ROUY, D ;
FOURNIER, C ;
CHAPMAN, JM ;
LAPLAUD, M ;
KOSCHINSKY, ML .
CHEMISTRY AND PHYSICS OF LIPIDS, 1994, 67-8 :369-380
[2]   Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo [J].
Biemond, BJ ;
Friederich, PW ;
Koschinsky, ML ;
Levi, M ;
Sangrar, W ;
Xia, JZ ;
Buller, HR ;
tenCate, JW .
CIRCULATION, 1997, 96 (05) :1612-1615
[3]  
DECLERCK PJ, 1993, THROMB HAEMOSTASIS, V70, P858
[4]   LIPOPROTEIN-ALPHA INHIBITS STREPTOKINASE-MEDIATED ACTIVATION OF HUMAN-PLASMINOGEN [J].
EDELBERT, JM ;
GONZALEZGRONOW, M ;
PIZZO, SV .
BIOCHEMISTRY, 1989, 28 (06) :2370-2374
[5]  
Edelstein C, 1997, J BIOL CHEM, V272, P11079
[6]   Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity -: Study in families with high lipoprotein (a) levels [J].
Falcó, C ;
Estellés, A ;
Dalmau, J ;
España, F ;
Aznar, J .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (04) :818-823
[7]   DOES LP(A) LIPOPROTEIN INHIBIT THE FIBRINOLYTIC SYSTEM [J].
HALVORSEN, S ;
SKJONSBERG, OH ;
BERG, K ;
RUYTER, R ;
GODAL, HC .
THROMBOSIS RESEARCH, 1992, 68 (03) :223-232
[8]   Lipoprotein(a) vascular accumulation in mice - In vivo analysis of the role of lysine binding sites using recombinant adenovirus [J].
Hughes, SD ;
Lou, XJ ;
Ighani, S ;
Verstuyft, J ;
Grainger, DJ ;
Lawn, RM ;
Rubin, EM .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1493-1500
[9]   CHARACTERIZATION OF THE ENZYME-ACTIVITY OF HUMAN PLASMA-LIPOPROTEIN (A) USING SYNTHETIC PEPTIDE-SUBSTRATES [J].
JAUHIAINEN, M ;
METSO, J ;
KOSKINEN, P ;
EHNHOLM, C .
BIOCHEMICAL JOURNAL, 1991, 274 :491-496
[10]   Lipoprotein(a): Structural implications for pathophysiology [J].
Koschinsky, ML ;
Marcovina, SM .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1997, 27 (01) :14-23